top of page
One in 10 people suffer from one or several of the 80 distinct chronic autoimmune diseases, or immune-mediated inflammatory diseases (IMIDs). These include the more common plaque psoriasis, rheumatoid arthritis and Crohn's disease but also orphan autoimmune diseases,
like systemic sclerosis, SLE and sarcoidosis.
There is a clear unmet medical need with the available drug treatments failing to successfully achieve disease remission.
OUR INNOVATIVE TECHNOLOGY
Methotrexate (MTX) is the 1st line, cornerstone drug treatment used to treat most of the chronic autoimmune disease.
MTX has held this place as first choice, because of its good safety profile. And in about 1/3 of the patients, it works really well as a mono-therapy. However, in the majority of the patients, other drugs need to be added in order to achieve disease remission.
For MTX to become optimally effective, it needs to be retained in the pro-inflammatory cells long enough to be poly-glutamated by intracellular enzymes.
With our proprietary NovoBioMed technology we trap drugs in the cells by transiently blocking their elimination via the ABCG2 gate. The result: with a lower overall drug dose we can reach higher intracellular levels of the activated drug faster.
Home: Quote
Home: Our Technology
With our innovative and insightful technology, we strive to enhance patients’ every day quality of life.
Home: Contact
GET IN TOUCH
Amplio Pharma BV
Hulstweg 11, PB1
1032 LB Amsterdam, the Netherlands
©2020 by Amplio Pharma B.V.
bottom of page